Cancer Invest.2021 Apr;39(4):285-296.doi: 10.1080/07357907.2021.1894570.Epub 2021 Mar 11.

本文采用的英格恩产品: 其它病毒感染增强试剂

The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System

Yijian Li  1   2 Qianqian Gao  2 Huan Liu  2 Shufen Lin  2 Huanyi Chen  2 Renpeng Ding  2 Ying Gu  2 Cheng-Chi Chao  2 Xuan Dong  2   3 Affiliations


The switchable chimeric antigen receptors (CARs) have shown many advantages in CAR T-cell therapy. However, human primary T-cells are required to evaluate antigen-specific adaptors by IFN-γ assay or FACS analysis, which limits the throughput of adaptor screening. A sensitive and robust CD16-CAR Jurkat NFAT-eGFP reporter system has been developed to assess the therapeutic efficacy of antibody-targeted CAR-T-cell by effectively evaluating the T-cell activation by various tumor cells and the impact of immune checkpoint inhibitor antibodies. This reporter system facilitates the screening of targeted antibodies in a high throughput manner for the development of improved T-cell immunotherapy.

Keywords: CD16-CAR; PD-L1; cetuximab; immunotherapy.